Expert Opinion on Therapeutic Patents

Papers
(The TQCC of Expert Opinion on Therapeutic Patents is 11. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
The role of patent analysis in target selection74
FAK inhibitors in cancer, a patent review – an update on progress38
Targeting the EGFR/RAS/RAF signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023)34
Traf2- and Nck-interacting kinase inhibitors: a patent review (2008–2024)32
RORγt inhibitors in clinical development for the treatment of autoimmune diseases: challenges and opportunities32
Recent advances in factor XII(a) inhibitors: an updated patent landscape (2020-present)32
Update on mGlu4 modulator patents: 2017 to present27
P2Y 12 R antagonists in antithrombotic therapy: a patent and literature review (2019–present)26
T-type calcium channel blockers: a review of recent advances (2018–2025)26
Recent developments of agents targeting Vibrio cholerae : patents and literature data26
An updated patent review of dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors (2020–present)25
Caspase inhibitors: a review on recently patented compounds (2016–2023)25
A patenting perspective of fat mass and obesity associated protein (FTO) inhibitors: 2017–present25
A patent review of hepatitis B virus core protein allosteric modulators (2019-present)23
An updated patent review of AKT inhibitors (2020 – present)22
Patent review of cannabinoid receptor type 2 (CB 2 R) modulators (2016-present)22
A patent review of MAPK inhibitors (2018 – present)20
Proteolysis-Targeting Chimeras (PROTACs) targeting the BCR-ABL for the treatment of chronic myeloid leukemia – a patent review20
Inhibition of GTPase KRAS G12D : a review of patent literature19
Antiprotozoal drugs: challenges and opportunities18
GPR120 agonists for the treatment of type 2 diabetes: an updated patent review (2020-present)18
An update on PDGFR inhibitors: a patent review (2020 - present)18
A patent review of LPAR1 antagonists (2010 – present)18
Targeting the LPA1 signaling pathway for fibrosis therapy: a patent review (2010-present)18
Insights and trends in development of TEAD–YAP/TAZ inhibitors: a review of PCT patents (2022 to June 2025)18
Synthetic lethality: targeting the SMARCA2 bromodomain for degradation in SMARCA4-deficient tumors – a review of patent literature from 2019–June 202318
Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2020–present)17
Recent advances in the development of P2Y 14 R inhibitors: a patent and literature review (2018-present)17
A patent review of IDH1 inhibitors (2018-present)17
Therapeutic compounds targeting interleukin-1 receptor-associated kinase 4 (IRAK4): an updated patent review (2019 to present)17
Small-molecule RNA ligands: a patent review (2018–2024)17
A patent review of NLRP3 inhibitors for inflammatory diseases (2023-present)16
A patent review of P2X7 receptor antagonists to treat inflammatory diseases (2018–present)16
An updated patent review of MALT1 inhibitors (2021–present)16
Phosphodiesterase 2 (PDE2) inhibitors: an updated patent review (2017–present)16
Biofilm and bacterial membrane vesicles: recent advances15
Novel fatty acid amide hydrolase (FAAH) inhibitors: a patent review from 2015 to 202515
The challenging inhibition of Aldose Reductase for the treatment of diabetic complications: a 2019–2023 update of the patent literature15
Antimalarial drugs: what’s new in the patents?15
An updated patent review on PD-1/PD-L1 antagonists (2022-present)15
A patent and literature review of CDK12 inhibitors15
The next generation of EGFR inhibitors: a patenting perspective of PROTACs based EGFR degraders15
Part-II: an update of Schiff bases synthesis and applications in medicinal chemistry-a patent review (2016-2023)14
A patent review of NLRP3 inhibitors to treat autoimmune diseases14
Are patents important indicators of innovation for Chagas disease treatment?14
Drugs and nanoformulations for the management of Leishmania infection: a patent and literature review (2015-2022)14
A patent review of von Hippel-Lindau (VHL)-recruiting chemical matter: E3 ligase ligands for PROTACs and targeted protein degradation (2019–present)14
Patent landscape and therapeutic evolution of mazdutide: a dual GLP-1/Glucagon receptor agonist for obesity and type 2 diabetes14
Trends in covalent drug discovery: a 2020–23 patent landscape analysis focused on select covalent reacting groups (CRGs) found in FDA-approved drugs14
An updated patent review of EZH2 inhibitors (2024–present)14
Recent patent landscape of ASK1 inhibitors: spotlight on 2-(1-isopropyl-4H-1,2,4-triazole-3-yl) pyridine as a privileged scaffold13
Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) in cancer: a patent review13
Small molecules targeting immune checkpoint proteins for cancer immunotherapy: a patent and literature review (2020–2024)13
An updated patent review of TRPA1 antagonists (2020 – present)12
Progress with polo-like kinase (PLK) inhibitors: a patent review (2018–present)12
The patent review of the biological activity of tropane containing compounds12
Biomedical applications of prokaryotic carbonic anhydrases: an update12
The management ofBabesia, amoeba and other zoonotic diseases provoked by protozoa12
An updated patent review of GPR40/ FFAR1 modulators (2020 – present)12
Sirtuin modulators: a review of patents from 2020 to 202412
Implementation and outcomes of China’s drug patent linkage system: lessons from international experience12
Correction12
5’-Ectonucleotidase (CD73) inhibitors: a patent review (2021-present)11
A patent review of histone deacetylase 8 (HDAC8) inhibitors (2013–present)11
Protein tyrosine phosphatase inhibitors: a patent review and update (2012–2023)11
Challenges, opportunities, and therapeutic potential of JAK inhibitors and their derived PROTACs (2022 – 2023)11
Histamine H 3 receptor antagonists/inverse agonists: a patent review (October 2017 – December 2023) documenting progress11
An insight into the last 5-year patents on Porphyromonas gingivalis and Streptococcus mutans , the pivotal pathogens in the oral cavity11
An updated patent review on rational combinations of HDAC inhibitors for cancer chemotherapy (2020 – present): part 1-patent granted11
1.4183819293976